Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly ...

After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, ...

Five-Star Business Finance Limited presented its Q2 FY2027 results on October 26, 2026, showcasing record quarterly disbursements and improved opera ...

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom ...

The Taylor City Council has approved a development agreement that could pave the way for a 664-acre data center campus just ...

Eledon Pharmaceuticals, Inc. (?Eledon?) (Nasdaq: ELDN) announced new positive patient-reported outcomes data from the Phase 2 BESTOW clinical trial of tegoprubart, its novel investigational ...

For patients with desmoid tumors, treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.

These data support the advancement of FT819 into the ongoing Phase 2 RECLAIM-LN study (FT819-201; NCT07570862) in patients with refractory, moderate-to-severe SLE with lupus nephritis, which uses the ...

Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative ...

As a company takes steps to transform the former Homer City Generating Station into what would be the largest natural ...

(9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase ...